Tracked deals
6
6 tracked deals across 2020-2024.
Public Company
Healthcare
Ginkgo Bioworks
Boston, Massachusetts, United States
Ginkgo Bioworks builds autonomous laboratories and related tools for biotechnology, replacing manual laboratory work with robotics and enabling “cloud lab” contract research through its platforms and solutions.
- Focus Areas
- Synthetic biology / cell programming, Autonomous labs for biotechnology, Cloud lab / contract research
- Website
- www.ginkgo.bio
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
5 buyout · 1 divestiture
Ginkgo Bioworks Acquisition Volume by Year
Last 3 years
Supporting Data
Recent Transactions
-
February 28, 2024
- Buyer
- Ginkgo Bioworks
- Target
- Patch Biosciences
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Ginkgo Bioworks has acquired Patch Biosciences, a startup that built an AI platform for sequence design to advance genetic medicines. The acquisition will integrate Patch's machine‑learning models and validated assays into Ginkgo's platform to expand its gene therapy, cell therapy and RNA therapeutics capabilities for biopharma customers.
-
February 28, 2024
- Buyer
- Ginkgo Bioworks
- Target
- Proof Diagnostics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Ginkgo Bioworks has acquired Proof Diagnostics to integrate Proof's OMEGA nuclease libraries and portable diagnostic technologies into Ginkgo’s gene therapy and genetic medicines platform. The deal expands Ginkgo’s gene editing toolkit and diagnostic capabilities to better serve customers developing programmable medicines and rapid detection systems.
-
July 25, 2022
- Buyer
- Ginkgo Bioworks (Ginkgo Bioworks, Inc.)
- Target
- Zymergen
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Ginkgo Bioworks (NYSE: DNA) has entered into a definitive agreement to acquire Zymergen (Nasdaq: ZY) in an all-stock transaction valued at approximately $300 million market capitalization. The deal is expected to close in the first quarter of 2023, pending Zymergen stockholder approval, regulatory approvals, and other customary closing conditions.
-
June 6, 2022
- Buyer
- Ginkgo Bioworks
- Target
- Bitome
- Seller
- Bitome
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Divestiture
Ginkgo Bioworks acquired certain assets from Bitome, a Boston-based developer of real-time metabolite monitoring technology, to integrate continuous metabolite monitoring into its cell engineering platform. The acquisition is intended to accelerate design-build-test-learn cycles and bioprocess optimization across Ginkgo’s portfolio of cell programs by providing real-time metabolic data and ML-driven insights.
-
January 19, 2022
- Buyer
- Ginkgo Bioworks
- Target
- Project Beacon COVID-19 LLC
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Type
- Buyout
Ginkgo Bioworks has acquired the assets and operations of Project Beacon COVID-19 LLC, a Boston-based social benefit organization that provided accessible COVID-19 testing across Massachusetts. The acquisition brings Project Beacon's partner relationships, digital platform, and personnel into Ginkgo’s Concentric by Ginkgo public health and biosecurity offering to expand COVID-19 monitoring and testing capabilities.
-
December 16, 2020
- Buyer
- Ginkgo Bioworks
- Target
- Novogy, Inc.
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
Ginkgo Bioworks acquired the main assets of Novogy, Inc., absorbing Novogy's strain assets, IP portfolio, codebase and most of its technical team. The acquisition brings Novogy's expertise in lipid-producing oleaginous yeasts (notably Yarrowia lipolytica) into Ginkgo's cell‑programming platform to accelerate development of bio-based oils, chemicals and materials.
Related Acquisition Pages
Selling a company? Get in front of buyers like Ginkgo Bioworks
Turn tracked acquisition activity into an outreach-ready buyer list.